Technology | 2018.11.23
Frost & Sullivan Publishes Q3-2018 Update Report on RedHill Biopharma Ltd.: RedHill published additional data from MAP US Phase III study of RHB-104 in Crohn's Disease; Steady-state sales in GI drugs; target price unchanged
Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program TEL AVIV, Israel, Nov. 23, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise the investors\' level of knowledge of TASE listed technology and...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]es-in-gi-drugs-target-price-un
